Mineralys Therapeutics Stock (NASDAQ: MLYS)

Dernières nouvelles pour Mineralys Therapeutics (NASDAQ:MLYS) Stock

MINERALYS THERAPEUTICS INC

Mineralys Therapeutics

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics Inc

WIIM

SAND

Sandstorm Gold shares are trading higher after announcing that Royal Gold will acquire them for $3.5 billion.

B of A Securities analyst Michael Funk reinstates T-Mobile US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) with a Neutral and announces $255 price target.

News

Price Target

Initiation

Analyst Ratings

TMUS

B of A Securities Reinstates Neutral on T-Mobile US, Announces $255 Price Target

ENVX

Enovix shares are trading higher after the company reported better-than-expected Q2 financial results.

Barclays analyst Betty Jiang initiates coverage on CNX Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNX#NYSE">CNX</a>) with a Equal-Weight rating and announces Price Target of $33.

Barclays Initiates Coverage On CNX Resources with Equal-Weight Rating, Announces Price Target of $33

B of A Securities analyst Michael Funk reinstates Verizon Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) with a Neutral and announces $45 price target.

B of A Securities Reinstates Neutral on Verizon Communications, Announces $45 Price Target

CRWV

CoreWeave shares are trading lower following an announcement to acquire Core Scientific in an all-stock deal.

B of A Securities analyst Michael Funk reinstates AT&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>) with a Buy and announces $32 price target.

B of A Securities Reinstates Buy on AT&T, Announces $32 Price Target

Barclays analyst David Strauss initiates coverage on Voyager Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOYG#NYSE">VOYG</a>) with a Equal-Weight rating and announces Price Target of $45.

VOYG

Barclays Initiates Coverage On Voyager Technologies with Equal-Weight Rating, Announces Price Target of $45

SHEL

Shell shares are trading lower after the company provided a Q2 update note stating expectations for adjusted earnings to be impacted by lower trade and optimisation.

STLA

Stellantis shares are trading lower after B of A Securities downgraded the stock from Buy to Neutral and cut its price target from $16.5 to $11.75.

B of A Securities analyst Ronald Epstein initiates coverage on Voyager Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOYG#NYSE">VOYG</a>) with a Buy rating and announces Price Target of $50.

B of A Securities Initiates Coverage On Voyager Technologies with Buy Rating, Announces Price Target of $50

Leerink Partners analyst Faisal Khurshid assumes AbCellera Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABCL#NASDAQ">ABCL</a>) with a Outperform rating and announces Price Target of $5.

ABCL

Leerink Partners Assumes AbCellera Biologics at Outperform, Announces Price Target of $5

Enovix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) ("Enovix"), a leader in advanced silicon battery technology, today announced the launch of the AI-1TM platform, its Artificial Intelligence ClassTM batteries for the next generation of mobile smartphones that require significantly higher total energy storage and power to perform AI functions locally. This revolutionary silicon-anode smartphone battery platform is protected by 190 Enovix architecture-specific patents that enable the use of 100% active silicon anodes. Last week, the company sampled its first 7,350 milliampere-hour (mAh) AI-1 batteries to a leading smartphone OEM for qualification in the first ever 100% silicon-anode battery smartphone launch.
With energy density exceeding 900 watt-hours per liter (Wh/L) and advanced capabilities for high discharge rate and long cycle life, Enovix believes AI-1 is the highest energy density battery commercially available in the market today. The company's patented battery architecture overcomes the notorious silicon anode swelling problems, enabling exceptional performance without compromising safety or longevity. The higher energy density provided by the AI-1 enables smartphone manufacturers to take full advantage of AI-enabled applications without requiring frequent charging cycles.&nbsp;&nbsp;
AI-1 Performance Highlights&#x2A;:
<ul>
<li>&gt;900 Wh/L energy density – highest commercially available</li>
<li>Fast charging at 3C rates – 20% charged in 5 minutes, 50% charged in 15 minutes</li>
<li>900+ cycles in standard smartphone usage based on initial unit testing</li>
<li>High discharge capability across wide temperature ranges – ideal for AI applications</li>
<li>Passed Enovix Safety Test Suite (ESTS): drop, tumble, thermal abuse, and external short circuit test</li>
</ul>

Enovix Launches AI-1 Silicon-Anode Battery Platform For Smartphones, Delivering Energy Density And Fast Charging For AI Applications

Management

Baxter Appoints Andrew Hider As CEO

B of A Securities analyst Michael Jacks downgrades Stellantis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) from Buy to Neutral and lowers the price target from $16.5 to $11.75.

Downgrades

B of A Securities Downgrades Stellantis to Neutral, Lowers Price Target to $11.75

Guidance

Enovix Sees Q2 2025 Revenue $7.5M Vs $5.572M Estimate; Sees Adj. EPS $(0.15) Vs $(0.174) Estimate

Newsmax Now Available Internationally on Truth+ Apps and the Web
SARASOTA, Fla., July 07, 2025 (GLOBE NEWSWIRE) -- Trump Media and Technology Group Corp. (Nasdaq, NYSE Texas: <a href="https://www.benzinga.com/stock/djt#Nasdaq,%20NYSE%20Texas">DJT</a>) ("Trump Media" or the "Company"), operator of the social media platform Truth Social, the streaming platform Truth+, and the FinTech brand Truth.Fi, announced today that the Company has successfully launched the Truth+ platform globally.
Streaming channels and video on demand content are now available globally on Truth+ apps for iOS and Android devices, on the Web, and on Truth+ apps for Apple TV, Android TV, Amazon Fire, and Roku connected TVs.
Additionally, the flagship Newsmax channel is now available on all international Truth+ apps and on the Web, which will greatly contribute to Newsmax's ongoing international expansion efforts.

Trump Media And Technology Group Launches Truth+ Platform Globally; Newsmax Now Available Internationally On Truth+ Apps And Web

PRZO

ParaZero Technologies shares are trading higher after the company announced it successfully achieved 100% effectiveness for DefendAir.

Leerink Partners analyst Faisal Khurshid initiates coverage on Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Outperform rating and announces Price Target of $88.

RYTM

Leerink Partners Initiates Coverage On Rhythm Pharmaceuticals with Outperform Rating, Announces Price Target of $88

General

UAVS

AgEagle Aerial Systems Announces Upcoming Demonstration Of AI-Enabled Unmanned Aircraft System Teaming

Press Releases

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

Health Care

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)

Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)

Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

Earnings

Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection

Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)

Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria

Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat

Comments

Mineralys Therapeutics

Actualités

Dernières nouvelles pour Mineralys Therapeutics (NASDAQ:MLYS) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL